RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 103 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $296,879 | +41.2% | 12,950 | +1.6% | 0.00% | +50.0% |
| Q2 2023 | $210,264 | -9.8% | 12,751 | -2.4% | 0.00% | 0.0% |
| Q1 2023 | $233,008 | -30.1% | 13,061 | +14.1% | 0.00% | -33.3% |
| Q4 2022 | $333,395 | +32.3% | 11,449 | +11.5% | 0.00% | 0.0% |
| Q3 2022 | $252,000 | +500.0% | 10,271 | +0.4% | 0.00% | – |
| Q2 2022 | $42,000 | -80.3% | 10,230 | +2.0% | 0.00% | -100.0% |
| Q1 2021 | $213,000 | +1.9% | 10,027 | +42.4% | 0.00% | 0.0% |
| Q4 2020 | $209,000 | – | 7,041 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 4,909,956 | $142,977,919 | 8.04% |
| Opaleye Management Inc. | 735,000 | $21,403,200 | 7.44% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $55,153,280 | 3.43% |
| RA Capital Management | 5,516,067 | $160,627,871 | 3.26% |
| Altium Capital Management LP | 170,000 | $4,950,400 | 2.52% |
| Samsara BioCapital, LLC | 345,293 | $10,054,932 | 2.16% |
| Rock Springs Capital Management LP | 1,760,865 | $51,276,389 | 1.23% |
| Parkman Healthcare Partners LLC | 157,862 | $4,596,941 | 1.22% |
| Baker Brothers Advisors | 6,354,608 | $185,046,185 | 1.11% |
| EAM Investors, LLC | 164,695 | $4,795,918 | 0.99% |